News

Data showed patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy and a high level of intertumoral heterogeneity.

UCLA researchers have discovered a new drug that helps reduce ascites in patients with ovarian cancer through inhibiting certain receptors.

Nivolumab (Opdivo) has been approved by the FDA as a single-agent to include the frontline treatment of patients with BRAF wild-type advanced melanoma.

The FDA has approved nivolumab (Opdivo) as a treatment for patients with metastatic renal cell carcinoma following prior treatment with an anti-angiogenic therapy.

A new method to elucidate the clonal relationship between tumors used tissues and clinical details from patients with contralateral breast cancer, and for the first time, next-generation sequencing.

A recent meta-analysis published in The Oncologist found that metformin use in patients with simultaneous diabetes and breast cancer improved overall survival (OS) and cancer-specific survival.

A combination of dabrafenib and trametinib has been approved by the FDA for patients with unresectable or metastatic BRAF-mutated melanoma, based on an extension in overall survival (OS) from two phase III studies.

A research team from Michigan Technological University recently discovered two major biomarkers used in the detection of thyroid cancer may be inaccurate in diagnosing the disease.

A combination of the oral proteasome inhibitor ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone has been approved by the FDA a full 4 months ahead of schedule for patients with multiple myeloma with at least 1 prior surgery.

A team of scientists have conducted preclinical trials of a novel drug nanocarrier, 3HM, that may offer a solution to breaking the blood-brain barrier in the treatment of brain cancers like glioblastoma multiforme.

A team of scientists from Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic may have found a way to increase sensitivity to the front-line chemotherapeutic agent temozolomide (TMZ) in glioblastoma (GBM), even after resistance.

Patients receiving a combination of MEK inhibitor trametinib and BRAF inhibitor dabrafenib not only greatly improves long-term outcomes, but also lowers some adverse events associated with either standalone agent for patients with BRAF-mutated metastatic melanoma.

Where once limited treatment options existed for patients with CLL, medical oncologists now have a plethora of agents from which to choose, making disease management in CLL more effective with fewer toxicities.

The treatment paradigm for renal cell carcinoma (RCC) could undergo major changes in the future due to several novel therapies in the works for regulatory approval and checkpoint inhibitors, vaccines, recombinant T-cell receptors, and bi-specific T-cell engagers.

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer (NMIBC) following first-line bacillus Calmette-Guerin (BCG) therapy.

Several recent trials have shown that a combination of docetaxel in conjunction with androgen deprivation therapy (ADT) is optimal in treating oligometastatic prostate cancer.

Despite the small size of the pigeon brain, our Columba livia counterparts have performed just as well as humans in distinguishing between normal tissue and breast cancer tissue in a study performed by researchers at the University of Iowa and the University of California, Davis.

Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).

Avelumab has been given breakthrough therapy designation by the FDA as a possible treatment for patients with metastatic Merkel cell carcinoma (MCC) following progression on at least one prior chemotherapy regimen

Select medical centers nationwide are now offering blue-light cystoscopy imaging to better detect papillary cancer of the bladder.

Bladder cancer may soon catch up to other areas of oncology in terms of an influx of immunotherapies, according to Thomas Powles, MD.

The PD-1 inhibitor nivolumab (Opdivo) has gained a priority review status from the FDA as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogenic therapy.

The FDA has given accelerated approval to the CD38-targeted monoclonal antibody daratumumab as a monotherapy for patients with multiple myeloma following at least 3 prior therapies a full four months ahead of schedule.

A supplemental new drug application has been submitted to the FDA for ibrutinib in conjunction with bendamustine and rituximab. The combination would treat patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Vitamin C, often used to fight colds and other pathogens, may also be a powerful weapon against colorectal cancer (CRC), according to a study published in Science.

A number of colorectal cancer care advocacy groups and the American Cancer of Radiology are lobbying Congress to pass the CT Colonography Screening for Colorectal Cancer Act, an initiative that could lower costs and increase screening rates.

From its approval in May 2013 to recently being considered as a combination treatment with other drugs, radium-223 dichloride shows great potential in positively impacting treatment for mCRPC, according to Dr. Michael Morris.

Dead bacteria cells and bacteria excretions from Clostridium sporogenes have successfully been used to kill colorectcal cancer cells in a preclinical study performed by researchers at the Nanyang Technological University in Singapore.

The FDA has given osimertinib (Tagrisso, AZD9291) an accelerated approval for treatment of patients with advanced EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) following progression on a prior EGFR TKI.

"We should be doing this, because we understand the disease, we see these patients, and we're not just surgeons, Dr. Adam Kibel said. "We were giving them medications to control their BPH before we diagnosed them with cancer."